Glycomic-Based Biomarkers for Ovarian Cancer: Advances and Challenges
View/ Open
Date
2021Author
Wanyama, Francis M
Blanchard, Véronique
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
Ovarian cancer remains one of the most common causes of death among gynecological malignancies afflicting women worldwide. Among the gynecological cancers, cervical and endometrial cancers confer the greatest burden to the developing and the developed world, respectively; however, the overall survival rates for patients with ovarian cancer are worse than the two aforementioned. The majority of patients with ovarian cancer are diagnosed at an advanced stage when cancer has metastasized to different body sites and the cure rates, including the five-year survival, are significantly diminished. The delay in diagnosis is due to the absence of or unspecific symptoms at the initial stages of cancer as well as a lack of effective screening and diagnostic biomarkers that can detect cancer at the early stages. This, therefore, provides an imperative to prospect for new biomarkers that will provide early diagnostic strategies allowing timely mitigative interventions. Glycosylation is a protein post-translational modification that is modified in cancer patients. In the current review, we document the state-of-the-art of blood-based glycomic biomarkers for early diagnosis of ovarian cancer and the technologies currently used in this endeavor.
Citation
Wanyama FM, Blanchard V. Glycomic-Based Biomarkers for Ovarian Cancer: Advances and Challenges. Diagnostics (Basel). 2021 Apr 1;11(4):643. doi: 10.3390/diagnostics11040643. PMID: 33916250; PMCID: PMC8065431.Publisher
university of nairobi
Rights
Attribution-NonCommercial-NoDerivs 3.0 United StatesUsage Rights
http://creativecommons.org/licenses/by-nc-nd/3.0/us/Collections
- Faculty of Health Sciences (FHS) [10385]
The following license files are associated with this item: